Table 2.
The risk of MACCE according to the presence of elevated sortilin* and other confounders
| Sortilin | Co-variable | n/N (%) | HR (95%CI) | p-value |
|---|---|---|---|---|
| Systolic hypertension | ||||
| ≤71 ng/ml | No (<140 mm Hg) | 13/278 (4.7%) | 1.00 | |
| Yes (≥140 mm Hg) | 11/80 (13.7%) | 3.89 (1.49 – 10.18) | <0.01 | |
| >71 ng/ml | No (<140 mm Hg) | 33/275 (12.0%) | 5.45 (2.14 – 13.20) | <0.001 |
| Yes (≥140 mm Hg) | 17/97 (17.5%) | 7.92 (3.22 – 19.49) | <0.001 | |
| Diabetes mellitus | ||||
| ≤71 ng/ml | No | 16/312 (5.1 %) | 1.00 | |
| Yes | 8/46 (17.4 %) | 2.33 (0.89 – 6.13) | 0.08 | |
| >71 ng/ml | No | 43/332 (13.0 %) | 3.39 (1.82 – 6.30) | <0.001 |
| Yes | 7/40 (17.5 %) | 4.96 (2.08 – 11.85) | <0.001 | |
| Ischemic heart disease | ||||
| ≤71 ng/ml | No | 16/289 (5.5 %) | 1.00 | |
| Yes | 10/69 (14.5 %) | 1.03 (0.34 – 3.11) | 0.96 | |
| >71 ng/ml | No | 39/328 (11.9 %) | 2.98 (1.64 – 5.42) | <0.001 |
| Yes | 9/44 (20.4 %) | 3.18 (1.38 – 7.35) | <0.01 | |
| Testosterone | ||||
| ≤71 ng/ml | ≥11.4 nmol/L | 6/178 (3.4 %) | 1.00 | |
| <11.4 nmol/L | 18/180 (9.5 %) | 2.94 (1.06 – 8.16) | <0.05 | |
| >71 ng/ml | ≥11.4 nmol/L | 24/183 (13.1 %) | 5.78 (2.19 – 15.26) | <0.001 |
| <11.4 nmol/L | 26/189 (13.8 %) | 5.98 (2.24 – 15.98) | <0.001 |
*
> vs. ≤median; n/N (%), number of MACCE per number quartile of serum sortilin level.
MACCE is defined as composite of cardiovascular death, non-fatal ST-elevation or non-ST-elevation myocardial infarction, unstable angina, and non-fatal stroke.
All the models adjusted for age, fat mass, smoking (current, former, never) and physical activity, vitamin K antagonist, angiotensin-converting enzyme inhibitors, diuretics, fibrates, osteoprotegerin, LDL-C, C-reactive protein, and mutually exclusively for testosterone, self-reported pharmacologically treated diabetes mellitus, and systolic blood pressure.